Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient

Table 1

Summary of ocular findings observed with ibrutinib.

Reference	Age (years)	Duration of ibrutinib treatment	Initial symptoms	Ophthalmologic findings	Treatment	Outcome
Bohn et al. [7]	65	1 day	Bilateral blurring of vision	Uveitis	Ibrutinib discontinued; significant improvement after local and oral steroids	Clinical improvement
Bohn et al. [7]	64	9 months	1-week blurring of vision and photophobia, with 3-day hyphema	Uveitis	Responded poorly with local steroids while continuing ibrutinib and with significant improvement when ibrutinib was discontinued	Clinical improvement
Chiu et al. [2]	60	1 year	Bilateral increase in floaters	Uveitis	Ibrutinib continued; resolved with topical steroids	Clinical improvement
Chiu et al. [2]	63	2 years	Left eye floaters	Uveitis and cystoid macular edema	Ibrutinib continued; responded well with topical and oral steroids initially, but with relapses of uveitis with cystoid macular edema	Clinical improvement, but with relapses
Chiu et al. [2]	69	1 year and 6 months	Right eye loss of vision and floaters	Uveitis	Ibrutinib was discontinued temporarily but restarted after a trial of topical and IV steroids	Clinical improvement
Chiu et al. [2]	66	3 years	3-week history of bilateral floaters	Uveitis	Ibrutinib continued; responded well with topical steroids	Clinical improvement
Saenz-de-Viteri and Cudrnak [8]	67	4 weeks	4-week history of bilateral blurry vision	Cystoid macular edema	Ibrutinib continued at a normal dose; responded well with topical steroids and NSAIDS	Clinical improvement
Ben-Avi et al. [9]	73	Over 3 years	Left eye decreased in vision	Cystoid macular edema	Ibrutinib was discontinued; responded well with topical steroids and NSAIDS	Clinical improvement
Kolomeyer et al. [10]	75	6 months	Blurring of vision after cataract surgery	Anterior chamber fibrinoid syndrome after cataract extraction	Unknown if ibrutinib was continued; responded well with topical steroids after 2 weeks	Clinical improvement